There are currently 1328 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
Promoting Healing Of Nerves Through Electrical Stimulation
NCT04662320
Recruiting
This study is evaluating a new therapeutic use of electrical stimulation to promote nerve healing and improve functional recovery following surgical intervention for nerve compression. A single dose of the therapeutic stimulation is delivered as part of the surgical intervention to address compression of the ulnar nerve at the elbow.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/20/2023
Locations: The Ohio State Univeristy - Department of Plastic and Reconstructive Surgery, Columbus, Ohio
Conditions: Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies
Register for Updates
Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients
NCT05716477
Recruiting
This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. Currently, doctors use a stool- based test such as the fecal immunochemical test (FIT) and visual tests such as a colonoscopy... Read More
Gender:
Female
Ages:
45 years and above
Trial Updated:
03/16/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Colorectal Carcinoma
Register for Updates
NT-3 Levels and Function in Individuals With CMT
NCT05011006
Recruiting
This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.
Gender:
All
Ages:
7 years and above
Trial Updated:
03/13/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Charcot-Marie-Tooth Disease, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
A Study Of The Selective PKC-β Inhibitor MS- 553
NCT03492125
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2023
Locations: The Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
Register for Updates
A Study of ICP-192 in Patients With Advanced Solid Tumors
NCT04565275
Recruiting
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
Register for Updates
Hydroxyurea Optimization Through Precision Study
NCT03789591
Recruiting
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatric sickle cell clin... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
03/09/2023
Locations: Nationwide Children's Hospital., Columbus, Ohio
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT05417308
Recruiting
This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early cessation of therapy in women undergoing treatment for breast cancer. Patients on endocrine therapy commonly report hair loss or thinning. Minoxidil is a drug that may promote... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/08/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endocrine Therapy-Induced Alopecia, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
The Spine Phenome Project
NCT05776771
Recruiting
The goal of this observational trial is to compare the health history and motion capabilities of participants with low back pain disorders to participants with healthy spines. The main question[s] it aims to answer are to: Primary outcomes of this research effort include composite measures that differentiate between control and patient populations, predict injury or reinjury risk, identify low back and neck pain patient phenotypes, and evaluate treatment effectiveness. Secondary outcomes of thi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2023
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Low Back Pain, Neck Pain
Register for Updates
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
NCT05665725
Recruiting
This phase I trial tests the safety and side effects of siltuximab in preventing CAR T cell therapy related cytokine release syndrome in patients with CD19 positive non-Hodgkin lymphoma. Several of the major complications of CD19 directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) include cytokine release syndrome (CRS, a complication of a highly active immune system seen with some cancer treatments including CD19.CAR-T cell therapy) and immune effector cell therapy associated neuroto... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Non-Hodgkin Lymphoma
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Columbus, Ohio
Conditions: Cystic Fibrosis
Register for Updates
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
All
Ages:
1 year and above
Trial Updated:
03/06/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Neuroblastoma
Register for Updates